NCT06436027View on ClinicalTrials.gov

Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.

CompletedOBSERVATIONAL
Enrollment

496

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Heart Transplant Rejection
Interventions
DIAGNOSTIC_TEST

Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling

Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.

Trial Locations (3)

90048

Cedars Sinai Medical Center, Los Angeles

Unknown

Paris Translational Research Center for Organ Transplantation, Paris

Center Gallucci of the University General Hospital of Padova, Padua

All Listed Sponsors
collaborator

Cedars Sinai Medical Center, Los Angeles, USA

UNKNOWN

collaborator

University of Padova

OTHER

lead

Paris Translational Research Center for Organ Transplantation

OTHER

NCT06436027 - Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling. | Biotech Hunter | Biotech Hunter